Cite
MLA Citation
J. P. Sharman et al.. “PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR'S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS).” HemaSphere, vol. 6, n.d., pp. 1744–1745. http://access.bl.uk/ark:/81055/vdc_100158013494.0x00002b